Show simple item record

dc.contributor.authorLapin, Morten
dc.contributor.authorHuang, Helen J.
dc.contributor.authorChagani, Sharmeen
dc.contributor.authorJavle, Milind
dc.contributor.authorShroff, Rachna T.
dc.contributor.authorPant, Shubham
dc.contributor.authorGouda, Mohamed A.
dc.contributor.authorRaina, Anjali
dc.contributor.authorMadwani, Kiran
dc.contributor.authorHolley, Veronica R.
dc.contributor.authorCall, S. Greg
dc.contributor.authorDustin, Derek J.
dc.contributor.authorLanman, Richard B.
dc.contributor.authorMeric-Bernstam, Funda
dc.contributor.authorRaymond, Victoria M.
dc.contributor.authorKwong, Lawrence N.
dc.contributor.authorJanku, Filip
dc.date.accessioned2022-04-13T01:51:29Z
dc.date.available2022-04-13T01:51:29Z
dc.date.issued2022-02
dc.identifier.citationLapin, M., Huang, H. J., Chagani, S., Javle, M., Shroff, R. T., Pant, S., Gouda, M. A., Raina, A., Madwani, K., Holley, V. R., Greg Call, S., Dustin, D. J., Lanman, R. B., Meric-Bernstam, F., Raymond, V. M., Kwong, L. N., & Janku, F. (2022). Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precision Oncology.en_US
dc.identifier.doi10.1200/po.21.00197
dc.identifier.urihttp://hdl.handle.net/10150/664002
dc.description.abstractPURPOSE IDH mutations occur in about 30% of patients with cholangiocarcinoma. Analysis of mutations in circulating tumor DNA (ctDNA) can be performed by droplet digital polymerase chain reaction (ddPCR). The analysis of ctDNA is a feasible approach to detect IDH mutations. METHODS We isolated ctDNA from the blood of patients with IDH-mutated advanced cholangiocarcinoma collected at baseline, on therapy, and at progression to isocitrate dehydrogenase (IDH) inhibitors. RESULTS Of 31 patients with IDH1R132 (n = 26) or IDH2R172 mutations (n = 5) in the tumor, IDH mutations were detected in 84% of ctDNA samples analyzed by ddPCR and in 83% of ctDNA samples analyzed by nextgeneration sequencing (NGS). Patients with a low variant allele frequency of ctDNA detected by NGS at baseline had a longer median time to treatment failure compared to patients with high variant allele frequency of ctDNA (3.6 v 1.5 months; P = .008). Patients with a decrease in IDH-mutated ctDNA on therapy by ddPCR compared with no change/increase had a trend to a longer median survival (P = .07). Most frequent emergent alterations in ctDNA by NGS at progression were ARID1A (n = 3) and TP53 mutations (n = 3). CONCLUSION Detection of IDH mutations in ctDNA in patients with advanced cholangiocarcinoma is feasible, and dynamic changes in ctDNA can correspond with the clinical course and clonal evolution.en_US
dc.language.isoenen_US
dc.publisherAmerican Society of Clinical Oncology (ASCO)en_US
dc.rights© 2022 by American Society of Clinical Oncology.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en_US
dc.titleMonitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitorsen_US
dc.typeArticleen_US
dc.identifier.eissn2473-4284
dc.contributor.departmentDivision of Hematology/Oncology, University of Arizona Cancer Centeren_US
dc.identifier.journalJCO Precision Oncologyen_US
dc.description.note12 month embargo; published 16 February 2022en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.pii10.1200/PO.21.00197
dc.source.journaltitleJCO Precision Oncology
dc.source.issue6


Files in this item

Thumbnail
Name:
po.21.00197.pdf
Embargo:
2023-02-16
Size:
288.6Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record